BR112015017432A2 - métodos para o tratamento de indicações cardiovasculares - Google Patents

métodos para o tratamento de indicações cardiovasculares

Info

Publication number
BR112015017432A2
BR112015017432A2 BR112015017432A BR112015017432A BR112015017432A2 BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2 BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A BR112015017432 A BR 112015017432A BR 112015017432 A2 BR112015017432 A2 BR 112015017432A2
Authority
BR
Brazil
Prior art keywords
methods
treating cardiovascular
cardiovascular indications
treating
indications
Prior art date
Application number
BR112015017432A
Other languages
English (en)
Portuguese (pt)
Inventor
Holzmeister Johannes
Original Assignee
Cardiorentis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ltd filed Critical Cardiorentis Ltd
Publication of BR112015017432A2 publication Critical patent/BR112015017432A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2242Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2221Relaxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
BR112015017432A 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares BR112015017432A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361756692P 2013-01-25 2013-01-25
PCT/IB2014/000253 WO2014115033A2 (en) 2013-01-25 2014-01-24 Methods of treating cardiovascular indications

Publications (1)

Publication Number Publication Date
BR112015017432A2 true BR112015017432A2 (pt) 2017-07-11

Family

ID=50382492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017432A BR112015017432A2 (pt) 2013-01-25 2014-01-24 métodos para o tratamento de indicações cardiovasculares

Country Status (19)

Country Link
US (2) US20140213520A1 (enExample)
EP (1) EP2948165A2 (enExample)
JP (1) JP2016505065A (enExample)
KR (1) KR20150108903A (enExample)
CN (1) CN105025918A (enExample)
AP (1) AP2015008624A0 (enExample)
AU (1) AU2014208851B2 (enExample)
BR (1) BR112015017432A2 (enExample)
CA (1) CA2898571A1 (enExample)
DO (1) DOP2015000175A (enExample)
EA (1) EA201500765A1 (enExample)
IL (1) IL239909A0 (enExample)
MX (1) MX2015009606A (enExample)
NZ (1) NZ710246A (enExample)
PH (1) PH12015501559A1 (enExample)
SG (1) SG11201505492XA (enExample)
TN (1) TN2015000315A1 (enExample)
TW (1) TW201442722A (enExample)
WO (1) WO2014115033A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184248A1 (en) * 2014-05-30 2015-12-03 Concert Pharmaceuticals, Inc. Methods of treating fibrotic diseases
CN105617360B (zh) * 2015-12-04 2018-12-21 中国农业大学 C-型钠肽在制备外用避孕药和精子功能检测试剂中的应用
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5461142A (en) 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
ES2188665T3 (es) 1994-06-02 2003-07-01 Forssmann Wolf Georg Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
NZ525389A (en) * 2000-10-04 2009-04-30 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
US8293711B2 (en) * 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086126A2 (en) * 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
CN104815319A (zh) * 2008-05-16 2015-08-05 科尔泰拉公司 治疗慢性心力衰竭的方法
WO2010048308A2 (en) * 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
JP2010116325A (ja) * 2008-11-11 2010-05-27 Institute For Protein Science Co Ltd Sirs患者を救命するためのペプチド組成物
US20110014180A1 (en) * 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
UY32902A (es) * 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
NZ710246A (en) 2016-11-25
WO2014115033A3 (en) 2015-02-26
WO2014115033A2 (en) 2014-07-31
JP2016505065A (ja) 2016-02-18
AU2014208851B2 (en) 2016-12-22
CA2898571A1 (en) 2014-07-31
MX2015009606A (es) 2016-04-26
DOP2015000175A (es) 2015-11-15
KR20150108903A (ko) 2015-09-30
US20140213520A1 (en) 2014-07-31
AU2014208851A1 (en) 2015-08-06
EA201500765A1 (ru) 2015-12-30
SG11201505492XA (en) 2015-08-28
US20140213519A1 (en) 2014-07-31
TN2015000315A1 (en) 2017-01-03
CN105025918A (zh) 2015-11-04
TW201442722A (zh) 2014-11-16
PH12015501559A1 (en) 2015-09-21
AP2015008624A0 (en) 2015-07-31
IL239909A0 (en) 2015-08-31
EP2948165A2 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
CO6761400A2 (es) Combinación de análogos de glucagón acilados con análogos de insulina
GT201300186A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
BR112015022197A2 (pt) tratamento de cataplexia
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
BR112014013780A8 (pt) transportador de seringa
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112015021681A2 (pt) proteínas de ligação para pcsk9
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112014011223A2 (pt) método de tratar uma doença proliferativa
BR112013033051A2 (pt) roda dentada com endentação inclinada e segmento para uma roda dentada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]